Ghassan K. Abou-Alfa, MD, on Tremelimumab Rechallenge in Unresectable HCC: Safety Outcomes

January 08, 2026 By The ASCO Post Staff

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, outlines an assessment of baseline characteristics and safety outcomes in HIMALAYA trial participants who were rechallenged with tremelimumab after being treated with the STRIDE regimen (single dose of tremelimumab plus regular-interval durvalumab) (Abstract 541).  

Related Content